Ingliforib (CP 368296) (Synonyms: CP 368296; GPi 296) |
Katalog-Nr.GC32658 |
Ingliforib (CP 368296) (CP 368296) ist ein Glykogen-Phosphorylase-Inhibitor mit IC50-Werten von 52, 352 und 150 nM fÜr Leber-, Muskel- und Gehirn-Glykogen-Phosphorylase und hat kardioprotektive AktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 186392-65-4
Sample solution is provided at 25 µL, 10mM.
Ingliforib is a glycogen phosphorylase inhibitor, with IC50s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity.
Ingliforib is a glycogen phosphorylase inhibitor, and inhibits the myocardial GP isoforms (muscle and brain) with IC50s of 352 and 150 nM, respectively, also a potent inhibitor of the liver isoform (IC50 of 52 nM). Ingliforib (0.1, 1, 10 μM) dose-dependently reduces infarct size in the isolated rabbit hearts[1].
Ingliforib (15 mg/kg) potently reduces infarct size by 52%, and decreases plasma glucose and lactate concentrations in openchest anesthetized rabbits. Ingliforib (15 mg/kg) also inhibits myocardial glycogen phosphorylase a (GPa) and total glycogen phosphorylase (GP) activity in anesthetized rabbits[1].
[1]. Tracey WR, et al. Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor. Am J Physiol Heart Circ Physiol. 2004 Mar;286(3):H1177-84.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *